Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from ELEVAI Labs Inc. ( (ELAB) ) is now available.
On August 12, 2025, PMGC Holdings Inc. announced amendments to consulting agreements with Northstrive Companies Inc. and GB Capital Ltd. These amendments include provisions for Acquisition Awards, which are incentives given upon the completion of acquisitions by the company or its subsidiaries. The awards are calculated as a percentage of the acquisition value, with the potential for an additional percentage based on the acquisition’s projected financial benefits or alignment with the company’s strategic goals. Additionally, the agreements’ names have been updated to reflect their focus on non-employee roles.
Spark’s Take on ELAB Stock
According to Spark, TipRanks’ AI Analyst, ELAB is a Underperform.
ELEVAI Labs Inc. is rated poorly due to major financial weaknesses, including negative revenue and cash flow issues, which are exacerbated by adverse technical indicators. The lack of favorable valuation metrics further weighs down the stock’s score. The absence of applicable corporate events means no positive catalysts are present to offset these challenges.
To see Spark’s full report on ELAB stock, click here.
More about ELEVAI Labs Inc.
Average Trading Volume: 572,248
Technical Sentiment Signal: Sell
Current Market Cap: $2.87M
For an in-depth examination of ELAB stock, go to TipRanks’ Overview page.